SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.32+2.7%Jan 12 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom pope who wrote (12309)7/12/2004 9:28:22 PM
From: Biomaven  Read Replies (4) of 52153
 
Well I'm definitely not in the mainstream here.

What the medical establishment have on their side is that high doses of statins work better than low doses, from which they have concluded that aggressively lowering cholesterol is the answer. On my side I have evidence that statins have many effects other than cholesterol lowering, and epidemiological data suggesting that low cholesterol in old people is bad.

Until we see some mortality effects from non-statin cholesterol-lowering drugs the jury will likely be out on who is right.

But from an investment perspective I know who is going to win - the makers of statins and perhaps some drugs like Zetia.

The guidelines with their focus on LDL barely give a nod to KOSP's Niaspan or Advicor. There again I'd bet that a statin plus Niaspan will do more for mortality than a statin plus another cholesterol-lowering agent.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News